Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma.

ABSTRACT:

Introduction

Glioblastoma (GBM) is the most common central nervous system malignancy in adults. Despite decades of developments in surgical management, radiation treatment, chemotherapy, and tumor treating field therapy, GBM remains an ultimately fatal disease. There is currently no definitive standard of care for patients with recurrent glioblastoma (rGBM) following failure of initial management.

Objective

In this retrospective cohort study, we set out to examine the relative effects of bevacizumab and Gamma Knife radiosurgery on progression-free survival (PFS) and overall survival (OS) in patients with GBM at first-recurrence.

Methods

We conducted a retrospective review of all patients with rGBM who underwent treatment with bevacizumab and/or Gamma Knife radiosurger

SUBMITTER: Zhang JF 

PROVIDER: S-EPMC10824796 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature